Nuvalent, Inc. (NUVL) 10-Year Financial Performance & Capital Metrics

NUVL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutNuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $0
EBITDA $0 +100.0%
Net Income -$261M -106.6%
EPS (Diluted) -3.93 -81.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -29.46% -35.8%
ROIC -32.62% +14.7%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Shares diluted 14.1% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-70.07%

EPS CAGR

10Y-

5Y-

3Y-

TTM-53.31%

ROCE

10Y Avg-151.57%

5Y Avg-151.57%

3Y Avg-26.69%

Latest-31.36%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	10.36M	16.91M	45.82M	86.11M	149.49M	280.37M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	612K	1.5M	10.26M	22.38M	36.25M	62.59M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	9.75M	15.4M	35.56M	63.73M	113.24M	217.77M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-10.36M	-16.91M	-45.82M	-86.11M	-149.49M	-280.37M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-0.63%	-1.71%	-0.88%	-0.74%	-0.88%
EBITDA+	0	-16.91M	-45.82M	-86.11M	-126.22M	0
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	-	-1.71%	-0.88%	-0.47%	1%
D&A (Non-Cash Add-back)	10.36M	0	0	0	0	280.37M
EBIT	-11.81M	-16.91M	-45.82M	-86.11M	-126.22M	-280.37M
Net Interest Income+	0	0	0	0	0	38.32M
Interest Income	0	0	0	0	23.27M	38.32M
Interest Expense	0	0	0	0	23.27M	0
Other Income/Expense	-1.45M	2.35M	-521K	4.25M	23.27M	20.38M
Pretax Income+	-11.81M	-14.56M	-46.34M	-81.85M	-126.22M	-259.99M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	764K
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-11.81M	-14.56M	-46.34M	-81.85M	-126.22M	-260.76M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-0.23%	-2.18%	-0.77%	-0.54%	-1.07%
Net Income (Continuing)	-11.81M	-14.56M	-46.34M	-81.85M	-126.22M	-260.76M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.24	-0.64	-2.13	-1.65	-2.17	-3.93
EPS Growth %	-	-1.67%	-2.33%	0.23%	-0.32%	-0.81%
EPS (Basic)	-0.24	-0.64	-2.13	-1.65	-2.17	-3.93
Diluted Shares Outstanding	48.28M	22.86M	21.78M	49.67M	58.22M	66.41M
Basic Shares Outstanding	48.28M	22.86M	21.78M	49.67M	58.22M	66.41M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	3.32M	10.65M	290.63M	477.99M	726.49M	1.13B
Cash & Short-Term Investments	3.02M	10.33M	288.11M	472.16M	719.9M	1.12B
Cash Only	3.02M	10.33M	68.53M	241.81M	335.39M	145.69M
Short-Term Investments	0	0	219.59M	230.36M	384.52M	972.61M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	314K	0	5.83M	6.58M	14.15M
Total Non-Current Assets+	0	0	3.2M	4.47M	5.9M	9.3M
Property, Plant & Equipment	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	0	3.2M	4.47M	5.9M	9.3M
Total Assets+	3.32M	10.65M	293.82M	482.46M	732.38M	1.14B
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	2.21%	26.6%	0.64%	0.52%	0.56%
Total Current Liabilities+	4.35M	4.38M	8.79M	19.48M	31.82M	54.02M
Accounts Payable	723K	1.25M	2.89M	7.2M	9.27M	5.22M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	-1000K	0	0	0	0	0
Other Current Liabilities	6.46M	2.59M	3.16M	7.43M	7.33M	0
Current Ratio	0.76x	2.43x	33.07x	24.54x	22.83x	20.96x
Quick Ratio	0.76x	2.43x	33.07x	24.54x	22.83x	20.96x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	16.22M	37.59M	2.89M	7.2M	0	17.94M
Long-Term Debt	2.17M	2.23M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	14.05M	35.35M	0	0	0	17.94M
Total Liabilities	20.57M	41.97M	8.79M	19.48M	31.82M	71.96M
Total Debt+	2.17M	2.23M	0	0	0	0
Net Debt	-843K	-8.1M	-68.53M	-241.81M	-335.39M	-145.69M
Debt / Equity	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-6.42x	-
Total Equity+	-17.26M	-31.32M	285.04M	462.98M	700.56M	1.07B
Equity Growth %	-	-0.82%	10.1%	0.62%	0.51%	0.53%
Book Value per Share	-0.36	-1.37	13.08	9.32	12.03	16.11
Total Shareholders' Equity	-17.26M	-31.32M	285.04M	462.98M	700.56M	1.07B
Common Stock	0	0	5K	6K	7K	8K
Retained Earnings	-17.33M	-31.89M	-78.22M	-160.08M	-286.3M	-547.05M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-14.05M	-280K	-228K	-494K	31K	-59K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.64M	-14.95M	-40M	-64.97M	-99.74M	-185.06M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-0.55%	-1.68%	-0.62%	-0.54%	-0.86%
Net Income	-11.81M	-14.56M	-46.34M	-81.85M	-126.22M	-260.76M
Depreciation & Amortization	0	0	215K	-373K	0	0
Stock-Based Compensation	41K	729K	3.55M	10.32M	25.56M	60.58M
Deferred Taxes	0	0	-215K	-5.74M	0	0
Other Non-Cash Items	1.57M	-2.39M	846K	5.74M	-10.11M	3.27M
Working Capital Changes	562K	1.27M	1.94M	6.93M	11.03M	11.84M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	424K	529K	1.64M	4.21M	2.17M	-4.05M
Cash from Investing+	0	0	-220.03M	-10.66M	-143.53M	-573.51M
Capital Expenditures	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	0	22.27M	318.22M	248.92M	336.85M	568.88M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	15K	-3.98M	286K	12.55M	-1.1M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-9.64M	-14.95M	-40M	-64.97M	-99.74M	-185.06M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-0.55%	-1.68%	-0.62%	-0.54%	-0.86%
FCF per Share	-0.20	-0.65	-1.84	-1.31	-1.71	-2.79
FCF Conversion (FCF/Net Income)	0.82x	1.03x	0.86x	0.79x	0.79x	0.71x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-36.53%	-21.89%	-21.7%	-29.46%
Return on Invested Capital (ROIC)	-	-	-38.81%	-29.51%	-38.24%	-32.62%
Interest Coverage	-	-	-	-	-6.42x	-
FCF Conversion	0.82x	1.03x	0.86x	0.79x	0.79x	0.71x

Frequently Asked Questions

Growth & Financials

Nuvalent, Inc. (NUVL) grew revenue by 0.0% over the past year. Growth has been modest.

Nuvalent, Inc. (NUVL) reported a net loss of $381.4M for fiscal year 2024.

Dividend & Returns

Nuvalent, Inc. (NUVL) has a return on equity (ROE) of -29.5%. Negative ROE indicates the company is unprofitable.

Nuvalent, Inc. (NUVL) had negative free cash flow of $263.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener